Robert Iannone Sells 2,403 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Robert Iannone sold 2,403 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $138.41, for a total transaction of $332,599.23. Following the sale, the chief marketing officer now directly owns 79,621 shares of the company’s stock, valued at $11,020,342.61. This represents a 2.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Robert Iannone also recently made the following trade(s):

• On Friday, March 7th, Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00.

Jazz Pharmaceuticals Stock Down 2.0 %

Jazz Pharmaceuticals stock traded down $2.70 during midday trading on Wednesday, reaching $134.16. The company’s stock had a trading volume of 766,031 shares, compared to its average volume of 771,293. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market capitalization of $8.15 billion, a P/E ratio of 18.90, a PEG ratio of 1.04 and a beta of 0.44. The stock’s 50-day simple moving average is $128.70 and its 200-day simple moving average is $120.40. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. Morgan Stanley reissued an “overweight” rating and set a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Truist Financial upped their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Finally, Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $190.53.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently bought and sold shares of JAZZ. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals during the 4th quarter valued at approximately $25,000. Quadrant Capital Group LLC grew its holdings in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 101 shares during the last quarter. Elequin Capital LP increased its position in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 183 shares during the period. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth $28,000. Finally, Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $29,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.